JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
- Myeloma Service
Filters
Save & Share
Clear Filters
Sorting 9 by
Memorial Sloan Kettering Cancer Center
New York, NY
- Accepting patients
- Accepting patients
- Accepting patients
- Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
- Accepting patients
Abramson Cancer Center - University of Pennsylvania (UPENN)
University of Pennsylvania
Philadelphia, PA
- Accepting patients
- Accepting patients
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
- Accepting patients
- Accepting patients
155 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.